Skip to main content
Signal8
PR Newswire releases

Study Finds NuLiv Science Ingredient, JointIQ®, Supports Supports Joint Health and Cartilage Markers in Active Adults

Published Updated

Source: PR NewswireView original on PR Newswire

BREA, Calif., Nov. 17, 2026 /PRNewswire/ -- NuLiv Science, a plant-based nutraceutical ingredients company, is sharing results from the first human clinical study on JointIQ®, its patented Astragalus membranaceus saponins (AMS) ingredient. The study, published in Nutrients, looked at how JointIQ® affects joint comfort, knee mobility, and cartilage-related markers in active adults.

NuLiv Science

Published in Nutrients (Evaluation of the Effect of Astragalus membranaceus Saponins Administration on Knee Function and Cartilage Biomarkers in Healthy Subjects with Knee Discomfort), the randomized, double-blind, placebo-controlled trial enrolled 50 adults who felt knee discomfort during activity but had no diagnosed joint condition. Each person took one capsule of JointIQ® or a placebo every day for 12 weeks. The researchers checked in at the start and again at Week 12, measuring how participants moved (a single-leg step-down test and knee range of motion), how their knees felt (the KOOS knee questionnaire), and a set of joint-related markers in their blood.

The standout results came from comparing JointIQ® against placebo. People taking JointIQ® reported a meaningful gain in knee-related quality of life, the strongest and most reliable finding in the study, and showed better knee extension mobility than the placebo group. The JointIQ® group also improved from where they started across the board: step-down performance rose by about 20%, recovery time after the test dropped by more than 33%, knee range of motion increased, and every category of the knee questionnaire improved, with the biggest gains in sport and recreation and in overall quality of life. The placebo group did not show those changes.

An early look at blood markers pointed in a joint-friendly direction. Within the JointIQ® group, markers tied to inflammation and cartilage wear (including IL-8, COMP, and MMP-13) went down, while PIINP, a marker of cartilage building, went up. The researchers describe these biomarker results as preliminary, and they line up with how JointIQ® has behaved in earlier laboratory studies of cartilage cells.

"We're really excited about this one. It's the first human study on JointIQ®, and it's a big moment for us in joint health," said Richard Wang, CEO of NuLiv Science. "We've built around Astragalus membranaceus for 25 years on traditional use and cell research. Now we have the human data to back our previous studies, and everything moved in the same direction."

For more information about JointIQ® and NuLiv Science's portfolio of clinically studied ingredients, visit www.nulivscience.com.

About NuLiv Science. NuLiv Science is a Certified B Corp and a plant-based nutraceutical ingredients company. Founded in 1997, NuLiv Science draws on the heritage of Traditional Chinese Medicine and partners with academic research institutions to develop branded specialty ingredients backed by published science.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/study-finds-nuliv-science-ingredient-jointiq-supports-supports-joint-health-and-cartilage-markers-in-active-adults-302941461.html

Share this release

Source: PR NewswireView original on PR Newswire

Content provided by PR Newswire. Redistribution, resale or sublicensing is not permitted.

    Study Finds NuLiv Science Ingredient, JointIQ®, Supports Supports Joint Health and Cartilage Markers in Active Adults | Signal8